RedHill Biopharma To Sponsor And Exhibit Its Ongoing Phase III Crohn's Program At The Israeli IBD Society Meeting

RedHill Biopharma Ltd. RDHL RDHL ("RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that it will provide Silver Sponsorship for the Israeli IBD (Inflammatory Bowel Disease) Society meeting to be held December 9, 2014 at the Dan Hotel in Tel-Aviv, Israel. The Israeli IBD Society meeting aims to promote collaborations and research initiatives in the field of diagnosis and treatment of inflammatory bowel diseases. As part of the accompanying exhibition, RedHill will present its flagship IBD program, RHB-104 for Crohn's disease, and the Phase III clinical study which is currently being conducted for RHB-104 in the U.S., Canada and Israel.